Cann began coverage on shares of Celgene Corp. (NASDAQ:CELG) in a research note issued to investors on Monday, The Fly reports. The firm issued an outperform rating and a $141.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on CELG. Leerink Swann restated a market perform rating and set a $135.00 price objective (up from $125.00) on shares of Celgene Corp. in a research report on Monday, August 1st. Vetr upgraded Celgene Corp. from a sell rating to a hold rating and set a $111.26 price objective on the stock in a research report on Monday, August 1st. Stifel Nicolaus restated a buy rating and set a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Morgan Stanley restated a hold rating and set a $120.00 price objective on shares of Celgene Corp. in a research report on Wednesday, August 3rd. Finally, BTIG Research upgraded Celgene Corp. from a neutral rating to a buy rating and upped their price objective for the company from $116.14 to $138.00 in a research report on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $136.77.

Celgene Corp. (NASDAQ:CELG) opened at 118.51 on Monday. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00. The stock has a market cap of $91.87 billion, a PE ratio of 45.01 and a beta of 1.71. The stock has a 50 day moving average price of $108.88 and a 200-day moving average price of $106.73.

Celgene Corp. (NASDAQ:CELG) last posted its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.10. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. During the same period in the previous year, the business earned $1.23 earnings per share. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, equities analysts expect that Celgene Corp. will post $5.92 EPS for the current year.

WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece can be accessed at http://www.dailypolitical.com/2016/12/01/cann-begins-coverage-on-celgene-corp-celg.html.

In other news, Director Richard W. Barker sold 20,000 shares of Celgene Corp. stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the sale, the director now owns 31,332 shares of the company’s stock, valued at approximately $3,472,212.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gilla Kaplan sold 9,710 shares of Celgene Corp. stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the sale, the director now directly owns 72,142 shares in the company, valued at approximately $7,678,794.48. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. First Financial Corp IN increased its stake in Celgene Corp. by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares during the period. Jolley Asset Management LLC increased its stake in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 450 shares during the period. Smithfield Trust Co. increased its stake in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares during the period. Integrated Investment Consultants LLC increased its stake in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 240 shares during the period. Finally, Cornerstone Advisors Inc. increased its stake in Celgene Corp. by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 884 shares during the period. Hedge funds and other institutional investors own 76.43% of the company’s stock.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

The Fly

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.